Zenas BioPharma, Inc. (ZBIO) - What Are Brokerages Saying About This Stock?

Key Points

• Analyst sentiment is moderately positive: Nine firms give Zenas BioPharma a consensus “Moderate Buy” rating—six buys, two holds, and one sell—with an average 12-month price target of $46.71.
• Recent quarterly results missed expectations: Zenas reported a loss of $1.65 per share versus the expected $1.24 loss, while revenue of $10 million came in below the $14.07 million consensus estimate.
• The shares opened at $25.93 after the article reported an 8.9% decline; their stated 12-month trading range was $13.50 to $44.60.

Shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $46.71.

Several equities research analysts have recently issued reports on ZBIO shares. Citigroup reaffirmed a "buy" rating on shares of Zenas BioPharma in a research note on Wednesday, October 28th. Wedbush restated an "outperform" rating and set a $45.00 price target on shares of Zenas BioPharma in a report on Wednesday, September 30th. HC Wainwright restated a "buy" rating and set a $44.00 price target on shares of Zenas BioPharma in a report on Tuesday, October 13th. Morgan Stanley began coverage on Zenas BioPharma in a research report on Tuesday, October 20th. They issued an "equal weight" rating and a $32.00 price target for the company. Finally, Guggenheim reaffirmed a "buy" rating and set a $55.00 price objective on shares of Zenas BioPharma in a research note on Wednesday, September 30th.

Zenas BioPharma Stock Down 8.9%

Shares of NASDAQ:ZBIO opened at $25.93 on Friday. The company has a current ratio of 9.93, a quick ratio of 9.93 and a debt-to-equity ratio of 1.57. Zenas BioPharma has a 12 month low of $13.50 and a 12 month high of $44.60. The company has a 50-day moving average price of $29.07 and a 200 day moving average price of $25.10. The company has a market cap of $1.69 billion, a price-to-earnings ratio of -2.88 and a beta of -0.88.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.24) by ($0.41). The business had revenue of $10.00 million during the quarter, compared to the consensus estimate of $14.07 million. As a group, equities research analysts predict that Zenas BioPharma will post -5.64 earnings per share for the current year.

Institutional Investors Weigh In On Zenas BioPharma

Several institutional investors have recently made changes to their positions in ZBIO. Candriam S.C.A. bought a new position in shares of Zenas BioPharma during the third quarter valued at approximately $17,725,000. Alps Advisors Inc. raised its holdings in shares of Zenas BioPharma by 35.6% in the third quarter. Alps Advisors Inc. now owns 86,369 shares of the company's stock worth $2,329,000 after buying an additional 22,694 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Zenas BioPharma during the 3rd quarter worth approximately $90,000. Sterling Capital Management LLC lifted its stake in shares of Zenas BioPharma by 1,090.0% during the 3rd quarter. Sterling Capital Management LLC now owns 1,190 shares of the company's stock worth $32,000 after acquiring an additional 1,090 shares during the last quarter. Finally, Engineers Gate Manager LP purchased a new position in Zenas BioPharma during the 2nd quarter valued at $329,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for autoimmune diseases and other serious immune-mediated conditions. The company's research is centered on treatments designed to modulate B-cell activity and restore balance to the immune system.

Zenas' lead product candidate is obexelimab, an investigational bifunctional antibody designed to bind CD19 on B cells and Fc gamma receptor IIb. By engaging both targets, obexelimab is intended to inhibit pathogenic B-cell activity without broadly depleting B cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.